As artificial intelligence continues to advance at a rapid pace, countries around the world are formulating strategies to balance the benefits of generative AI with its potential risks. This post ...
President Donald Trump's nomination of Brian D. Quintenz to serve as Chairman of the Commodity Futures Trading Commission (CFTC or Commission) portends a potential shift towards a more ...
As AI capabilities accelerate, governments are adopting markedly different approaches to governance - ranging from binding statute and sector-led oversight to decentralised regulatory models and ...
After a 2023 that witnessed several significant bank failures, here's how bank regulators should be thinking about the danger of bank runs, writes Eugene Ludwig, CEO of Ludwig Advisors and former ...
Exclusive: House Majority Whip Tom Emmer and Rep. Patrick McHenry are seeking clarity on the Securities and Exchange Commission’s regulatory approach to a method of distributing crypto tokens known as ...
As efforts to regulate AI around the globe gain steam, AI developers are keeping their eyes out for red flags—regulations or regulatory actions aimed at keeping the dark side of AI at bay that they ...
Cloud computing is a cornerstone of digital transformation across APEC economies, driving economic growth, business efficiency, and innovation. The region’s cloud market is expanding rapidly, but ...
As we journey toward the global mass adoption of blockchain, we confront formidable challenges. The community's steadfast pursuit of completely decentralized, anonymous transactions collides with a ...
The advent of artificial intelligence (AI) and data-driven methodologies has triggered a wave of transformation in regulatory compliance and quality assurance for the development of medical devices.
The Global Regulatory Brief provides monthly insights on the latest risk and regulatory developments. This brief was written by Bloomberg’s Regulatory Affairs Specialists. As technology continues to ...
GUILDFORD, SURREY / ACCESS Newswire / February 13, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumor cell (CTC) intelligence, with tests and services supporting research, drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results